EOM Pharmaceuticals Holdings Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on EOM Pharmaceuticals Holdings's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, EOM Pharmaceuticals Holdings has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How EOM Pharmaceuticals Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -5 | 2 | 1 |
| 31 Mar 22 | 0 | -5 | 1 | 1 |
| 31 Dec 21 | 0 | -5 | 1 | 1 |
| 30 Sep 21 | 0 | -4 | 2 | 2 |
Quality Earnings: Insufficient data to determine if IMUC has high quality earnings.
Growing Profit Margin: Insufficient data to determine if IMUC's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMUC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare IMUC's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if IMUC's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: IMUC has a negative Return on Equity (0%), as it is currently unprofitable.